SUPIMA
6.10.2020 15:02:14 CEST | Business Wire | Press release
Supima presents the 3rd annual Supima Design Lab in its very first all-digital format, which will take place on Thursday, October 8th and be streamed live on Supima’s Instagram along with Fashion Network. Once again Supima brings together a select group of up and coming and leading designers from around the world. This year’s Supima Design Lab will showcase exclusive collections designed using American-grown Supima cotton featuring designs by the winner and finalists of the 2020 Supima Design Competition, the selection of the 2020 Hyères Fashion & Photography Festival and by leading International designers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005256/en/
Created exclusively for the Supima Design Lab, each design showcases the endless possibilities of fabrics made with Supima cotton. Stemming from a commitment to design, sustainable innovation and superior quality, Supima is unwavering in its ongoing programs that create platforms for designers to express themselves despite the challenges of Covid-19.
This Year’s Digital Runway show will be presenting “Made with Supima” Exclusive Designs by;
The Winner and Finalists of the 13th Annual Supima Design Competition
Amanda Forastieri, Drexel University – This Year’s Winner
Sakura Mizutani , Fashion Institute of Design & Merchandising
Jenny Feng , Fashion Institute of Technology
Jennie Nguyen , Kent State University
Terrence Zhou , Parsons School of Design
Kyra Buenviaje , Rhode Island School of Design
Finalists of 35th International Festival of Fashion, Fashion Photography and Accessories of Hyères
Katarzyna Agnieszka (France) Andrea Grossi (Italy)
Aline Boubert (France) Marvin M’Toumo (France)
Xavier Brisoux (France) Maximilian Rittler (Belgium)
Emma Bruschi (France) Céline Shen (France)
Timour Desdemoustier (Belgium) Tom van der Borght (Belgium)
Selected Leading Designers
Thierry Colson
Lutz Huelle
Dice Kayek
Jean Paul Knott
On Aura Tout Vu
As a special addition to this year’s Supima Design Lab, there will be a round table orchestrated by Benjamin Simmenauer, Permanent Professor at Institut Français de la Mode, Fashion Expert & Brand Strategist. The round table includes a select panel of industry leaders for an in-depth discussion of the Supima Design Lab - From the Fields to the Runway. This year’s panelists include :
Jean-Pierre Blanc , Founder, International Festival of Fashion, Photography and Accessories of Hyères
Godfrey Deeny , International Editor-in-Chief, FashionNetwork
Marc Lewkowitz , President & CEO, Supima
Buxton Midyette , VP Marketing & Promotions, Supima
« We are truly honored to continue working with our SDC Partner School finalists, the selection from the Festival de Hyères and our Leading Designer group. During the pandemic, we knew it was more important than ever to stay nimble and shift the Supima Design Lab into a virtual format to support these emerging designers achieve success in the fashion industry »
Buxton Midyette, VP Marketing & Promotions, Supima
About Supima :
Supima is America’s premium cotton. Founded in 1954, the Supima brand, short for « Superior Pima », designates an elite variety of pima cotton sustainably grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color and indulgent softness.
Follow Us on Social:
Instagram: @Supima
Facebook: @Supima
Twitter: @Supima
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005256/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom